Clinical Perspectives Selecting 2L Treatment Options in R/R FL: Chemoimmunotherapy vs Lenalidomide Combinations in Relapsed Disease

Panelists discuss how their treatment approaches in the second-line (2L) setting for relapsed or progressive follicular lymphoma (R/R FL) are influenced by factors such as the duration of response to first-line therapy, tumor burden, and symptomatology, while also exploring the use of chemoimmunotherapy, lenalidomide combinations, and anti-CD20 monotherapy in clinical decision-making.

EP: 1.Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease

Now Viewing

EP: 2.Clinical Perspectives Selecting 2L Treatment Options in R/R FL: Chemoimmunotherapy vs Lenalidomide Combinations in Relapsed Disease

Video content above is prompted by the following:

For those with progression of disease, what is your treatment approach in the 2L setting? How do you factor in the duration of response to 1L therapy in selecting your 2L option as well as patient factors such as those with high tumor burden and/or symptomatic disease?
How often are you utilizing chemoimmunotherapy with an anti-CD20 in the 2L setting? What percentage of your patients are receiving a bendamustine-based or cyclophosphamide-based regimen in the 1L setting?
What is your treatment approach in selecting lenalidomide in combination with anti-CD20 vs anti-CD20 monotherapy?
What patient and/or disease factors do you consider?
Please feel free to comment on any differences and/or similarities in practice when selecting lenalidomide monotherapy vs in combination with anti-CD20 vs anti-CD20 monotherapy.